IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Clinical trials for IMMUNE THROMBOCYTOPENIC PURPURA (ITP) explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIC PURPURA (ITP) trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIC PURPURA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Extended trial tests bleeding disorder Drug's staying power
Disease control Recruiting nowThis study continues testing mezagitamab, an injectable drug, in adults with chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets and increases bleeding risk. The main goal is to check the long-term safety and side effects of the treatment …
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New injection aims to stop dangerous bleeding in chronic immune disorder
Disease control Recruiting nowThis study is testing whether a new drug called mezagitamab, given as an injection under the skin, can help adults with chronic immune thrombocytopenia (ITP) maintain safe platelet levels. ITP is a condition where the immune system mistakenly destroys platelets, increasing the ri…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug trial aims to help teens with rare bleeding disorder
Disease control Recruiting nowThis study is testing a drug called efgartigimod in teenagers (12 to under 18 years old) who have chronic immune thrombocytopenia (ITP), a condition where the immune system attacks blood platelets. The main goal is to find the correct dose and see if it helps increase and maintai…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC